Does Rallies show 13F holders for COCH?

Yes. Rallies tracks hedge fund and 13F ownership data for COCH, including fund names, share counts, latest tracked quarter, and position changes when available.

Is COCH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for COCH. It does not provide personalized investment advice.

COCH (Envoy Medical, Inc. Class A Common Stock) Stock Analysis - Hedge Fund Holdings

Envoy Medical, Inc. Class A Common Stock (COCH) is a publicly traded Healthcare sector company. As of May 20, 2026, COCH trades at $0.73 with a market cap of $54.86M and a P/E ratio of -0.60. COCH moved +0.00% today. Year to date, COCH is +6.37%; over the trailing twelve months it is -56.47%. Its 52-week range spans $0.36 to $3.60. Analyst consensus is buy with an average price target of $2.50. Rallies surfaces COCH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns COCH stock?

Hedge funds tracked by Rallies that own COCH include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Envoy Medical, Inc. Class A Common Stock.

COCH Key Metrics

Key financial metrics for COCH
Metric	Value
Price	$0.73
Market Cap	$54.86M
P/E Ratio	-0.60
EPS	$-1.23
Dividend Yield	0.00%
52-Week High	$3.60
52-Week Low	$0.36
Volume	32.36K
Avg Volume	0
Revenue (TTM)	$241.00K
Net Income	$-23.76M
Gross Margin	-262.66%

Top Hedge Funds Holding COCH

Citadel Advisors holds 28.31K shares of COCH, changed +0.00% as of Dec 31, 2024.
Renaissance Technologies holds 10.55K shares of COCH, changed +0.00% as of Mar 31, 2024.

Latest COCH News

Envoy Medical Secures Four Patents Covering Implantable Cochlear Systems, Battery Safety — May 20, 2026
Envoy Medical Completes Activation for 56 Acclaim Implant Patients, Eyes FDA PMA — Apr 22, 2026
Envoy Medical Appoints McKhann After $1.16B, $615M Exits; Acclaim® Trial Complete — Apr 16, 2026
Envoy Medical Gets FDA Nod for Final Acclaim Trial Stage, Wipes Out $32M Debt — Mar 23, 2026
Envoy Medical Hits 56-Patient Enrollment Milestone in Acclaim Trial — Mar 11, 2026

Recent COCH Insider Trades

Patel Mona Chetan bought 312.50K (~$125.00K) on Feb 12, 2026.
Potashnick Robert bought 212.50K (~$85.00K) on Feb 12, 2026.
Kantor Susan bought 96.15K (~$38.46K) on Feb 12, 2026.

COCH Analyst Consensus

1 analysts cover COCH: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.50.

Common questions about COCH

Who owns COCH stock?: Hedge funds tracked by Rallies that own COCH include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Envoy Medical, Inc. Class A Common Stock.
Does Rallies show 13F holders for COCH?: Yes. Rallies tracks hedge fund and 13F ownership data for COCH, including fund names, share counts, latest tracked quarter, and position changes when available.
Is COCH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for COCH. It does not provide personalized investment advice.